Table 3 |
|||||||||
|
vivo kinetics of killing of C. elegans infected by E. coli grown in urine samples after consumption of the different proanthocyanidins regimens. |
|||||||||
|
A |
LT50 Median (IC95%) in days |
P |
|||||||
|
|
|||||||||
|
Regimen |
Placebo |
18 mg |
36 mg |
72 mg |
Pl vs 18/36 |
18 vs 36 |
36 vs 72 |
6 h vs 24 h |
Sp-Fr vs Ja-Hu |
|
|
|||||||||
|
Spain |
|||||||||
|
|
|||||||||
|
1-6 h |
3.5 [3-5] |
5 [3-7] |
6 [5-8] |
ND |
<0.001 |
<0.001 |
ND |
NS except for 72 mg |
|
|
|
|||||||||
|
24 h |
3 [3-6] |
4.5 [3-6] |
5 [3-6] |
ND |
<0.001 |
NS |
ND |
<0.001 |
|
|
|
|||||||||
|
France |
<0.001 |
||||||||
|
|
|||||||||
|
1-6 h |
3 [3-5] |
5 [4-7] |
5.5 [4-7] |
ND |
<0.001 |
NS |
ND |
NS except for 36 mg |
|
|
|
|||||||||
|
24 h |
3 [3-5] |
3 [2-4] |
5 [4-8] |
ND |
NS |
<0.001 |
ND |
<0.001 |
|
|
|
|||||||||
|
Japan |
|||||||||
|
|
|||||||||
|
1-6 h |
4 [3-5] |
ND |
6.5 [5-9] |
7 [5-9] |
<0.001 |
ND |
NS |
NS |
|
|
|
|||||||||
|
24 h |
4 [3-5] |
ND |
5.5 [4-8] |
6 [4-8] |
<0.001 |
ND |
NS |
||
|
|
<0.001 |
||||||||
|
Hungary |
|||||||||
|
|
|||||||||
|
1-6 h |
3 [3-5] |
ND |
5 [4-8] |
6 [5-10] |
<0.001 |
ND |
NS |
NS |
|
|
|
|||||||||
|
24 h |
4 [3-5] |
ND |
5 [4-8] |
6 [4-9] |
<0.001 |
ND |
NS |
||
|
|
|||||||||
|
Total |
|||||||||
|
|
|||||||||
|
1-6 h |
3 [3-5] |
5 [3-7] |
5.5 [4-9] |
6.5 [5-10] |
<0.001 |
NS |
<0.001 |
NS |
ND |
|
|
|||||||||
|
24 h |
3.5 [3-5] |
4 [2-6] |
5 [3-8] |
6 [4-9] |
<0.001 |
<0.001 |
<0.001 |
ND |
|
|
|
|||||||||
|
OP50 |
6 [6-7] |
||||||||
|
|
|||||||||
|
B |
LT100 Median (IC95%) in days |
P |
|||||||
|
|
|||||||||
|
Regimen |
Placebo |
18 mg |
36 mg |
72 mg |
Pl vs 18/36 |
18 vs 36 |
36 vs 72 |
6 h vs 24 h |
Sp-Fr vs Ja-Hu |
|
|
|||||||||
|
Spain |
|||||||||
|
|
|||||||||
|
1-6 h |
8.5 [7-8] |
10 [9-10] |
11.5 [11-12] |
ND |
<0.001 |
<0.001 |
ND |
NS except for 72 mg |
<0.001 |
|
|
|||||||||
|
24 h |
7 [6-8] |
9 [8-10] |
9.5 [9-10] |
ND |
<0.001 |
NS |
ND |
<0.001 |
|
|
|
|||||||||
|
France |
|||||||||
|
|
|||||||||
|
1-6 h |
7 [6-8] |
10 [9-11] |
11 [10-12] |
ND |
<0.001 |
NS |
ND |
NS except for 36 mg |
|
|
|
|||||||||
|
24 h |
7 [6-8] |
8 [7-9] |
10.5 [10-11] |
ND |
NS |
<0.001 |
ND |
<0.001 |
|
|
|
|||||||||
|
Japan |
<0.001 |
||||||||
|
|
|||||||||
|
1-6 h |
8 [7-8] |
ND |
12.5 [12-13] |
13 [12-14] |
<0.001 |
ND |
NS |
NS |
|
|
|
|||||||||
|
24 h |
7.5 [7-8] |
ND |
11 [10-12] |
12 [11-13] |
<0.001 |
ND |
NS |
||
|
|
|||||||||
|
Hungary |
|||||||||
|
|
|||||||||
|
1-6 h |
7 [6-8] |
ND |
12 [11-13] |
12.5 [12-13] |
<0.001 |
ND |
NS |
NS |
|
|
|
|||||||||
|
24 h |
8 [7-8] |
ND |
11 [10-12] |
11.5 [11-12] |
<0.001 |
ND |
NS |
||
|
|
|||||||||
|
Total |
|||||||||
|
|
|||||||||
|
1-6 h |
7 [6-8] |
5 [3-7] |
5.5 [4-9] |
6.5 [5-10] |
<0.001 |
NS |
<0.001 |
NS |
ND |
|
|
|||||||||
|
24 h |
8 [7-8] |
4 [2-6] |
5 [3-8] |
6 [4-9] |
<0.001 |
<0.001 |
<0.001 |
ND |
|
|
|
|||||||||
|
OP50 |
14 [13-15] |
||||||||
|
|
|||||||||
|
(A) Determination of LT50 Median; (B) Determination of LT100 Median. |
|||||||||
|
Howell et al. BMC Infectious Diseases 2010 10:94 doi:10.1186/1471-2334-10-94 |
|||||||||
